02:24 PM EDT, 03/18/2024 (MT Newswires) -- Oculis Holding ( OCS ) shares fell more than 3% in recent Monday trading despite the company's narrower Q4 loss and increased cash position that it said will help fund its operations through late 2025.

The company reported a diluted Q4 loss of 0.34 Swiss francs ($0.38) per share, compared with a loss of 2.62 francs a year earlier. No forecasts were available from Capital IQ.

As expected, no revenue was reported for both Q4 ending Dec. 31, 2023 and the whole year.

As of Dec. 31, 2023, the company said it had total cash, cash equivalents and short-term investments of 91.7 million francs, or $108.9 million, compared with 19.8 million francs a year earlier.

The company said it is on track to report topline data in Q2 from the phase 2b trial of licaminlimab, OCS-02, for treating dye eye disease.

It expects to release topline results in Q4 from the second phase 3 trial evaluating OCS-01, a once-a-day eye drop for the treatment of inflammation and pain following cataract surgery. If positive, the company said the data along with the positive results of the previous trial will support the submission of a new drug application.

Oculis also said it aims to achieve this year an investigational new drug status for OCS-05 for the treatment of glaucoma.

Price: 11.43, Change: -0.41, Percent Change: -3.46